1,5-Dimethyl-1H-pyrrole-2-carboxamidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1,5-Dimethyl-1H-pyrrole-2-carboxamidine
• 英文别名: 1,5-dimethylpyrrole-2-carboximidamide
• 化学式: C₇H₁₁N₃
• mdl: MFCD05662988
• 分子量: 137.18
• InChiKey: ZJGZSOPQLOXMAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  54.8
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• [EN] BRIDGED BICYCLIC KALLIKREIN INHIBITORS<br/>[FR] INHIBITEURS BICYCLIQUES PONTÉS DE LA KALLIKRÉINE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2016201052A1

  公开（公告）日：2016-12-15

  Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.

  本文提供了调节激肽酶的化合物、包含这些化合物的药物组合物，以及它们的用途。
• Potassium channel modulators
  申请人：Cadent Therapeutics, Inc.

  公开号：US10774064B2

  公开（公告）日：2020-09-15

  Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.

  本发明提供了式 (I) 的新型化合物：及其药学上可接受的盐类，它们可用于治疗各种可受钾通道调节影响的疾病、失调或病症。还提供了包含式（I）新型化合物及其药学上可接受的盐的药物组合物，以及将其用于治疗一种或多种与钾通道相关的疾病、失调或病症的方法。
• BRIDGED BICYCLIC KALLIKREIN INHIBITORS
  申请人：GLOBAL BLOOD THERAPEUTICS, INC.

  公开号：US20160362427A1

  公开（公告）日：2016-12-15

  Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.
• POTASSIUM CHANNEL MODULATORS
  申请人：Cadent Therapeutics, Inc.

  公开号：US20190218200A1

  公开（公告）日：2019-07-18

  Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.
• US9815853B2
  申请人：——

  公开号：US9815853B2

  公开（公告）日：2017-11-14